Abstract

Anti-IL-4/13 therapies, guided by knowledge of an individual's underlying pathophysiology, are a promising class of therapies for treatment of asthma.

Original languageEnglish
Pages (from-to)570-575
Number of pages6
JournalCurrent opinion in allergy and clinical immunology
Volume14
Issue number6
DOIs
StatePublished - 2014

Keywords

  • Asthma
  • IL-13
  • IL-4
  • Monoclonal antibody

Fingerprint

Dive into the research topics of 'Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes'. Together they form a unique fingerprint.

Cite this